The combined antiviral effect of dextran sulphate (OS, MW 40000) and acyclovir (ACV) on herpes simplex virus type 1 (HSV-1) and pseudorabies virus (PRV) in vitro and on experimental HSV-1 keratitis in rabbits, was studied, Dextran sulphate ilJ' combination with ACV results in synergistic effect,.a,'$ measured by yield ';'.' .~r 
eduction assay and on herpes",simplex keratitis in rabbits. The better therapeutic effect of the combination was proved by the decreased severity 'of ocular infection and the reduction of the virus shedding in tear film.
Dextran sulphate has been shown to be a potent and selective inhibitor of the in vitro replication of human immunodeficiency virus (HIV) (Ito et aI., 1987; Ueno and Kuno, 1987) , herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, Sindbis virus (Baba et aI., 1988b) and arenaviruses (Andrei and De Clercq, 1990) .Sulphated polysaccharides act on virus adsorption (Baba et al., 1988a (Baba et al., , 1988b . It seems likely that one or more of the surface glycoproteins must be involved in attachment (Spear,1985; Mitsuya etal.,1988) .
Highly sulphated dextrans have been reported to act synergistically with AZT against HIV (Ueno and K1Jno, 1987) and simian type D retrovirus (Tsai et al., 1990) in vitro. It seems that dextran sulphate given alone or in combination with other drugs may be a candidate for experimental trials to determine its efficacy in inhibiting also in vivo virus replication. In this study, we investigated the effect of combination of dextran sulphate with acyclovir on the replication of HSV-1 and pseudorabies virus in vitro and on experimental herpes simplex keratitis in rabbits in vivo. (CEF) . The activity of the combination of DS and ACV was evaluated against HSV-1 in HESMF cells and against PRY in CEF cells using the yield reduction method. Dextran sulphate was present during virus adsorption as well as later, while ACV was added after adsorption of the virus. In tests which were run in parallel with the antiviral assays in confluent cell monolayers (which had not been infected) the compounds separately or in combination were not toxic to the host cells. Cytotoxicity was monitored by trypan blue dye exclusion. Preliminary investigation found that OSwas not toxic to the host cells at concentrations up to 375!J.g mr',
As shown in Table 1 , the degree of virus yield reduction by the combinations was considerably higher than that shown by the individual compounds. Reduction in HSV-1 titre by 0.5!J.g mr' of ACV or 5!J.g ml-1 of DS was 32-and 320-fold, respectively. When the drugs were combined, complete Virus reduction (>10 5-fold) was achieved, thus indicating strong synergism. Significant synergism was also obtained with ACV and DS against PRY.
For in vivo analyses, scarified eyes of Chinchil rabbits (2.1-2.8kg) were bilaterally inoculated, by dropping in each eye a 40!J.1 suspension of HSV-1 (DA strain) containing 10 6 CCID 50 per ml into the lower cul-de-sac and gently rubbing the lid over the cornea for 30s. The rabbits were divided into four groups (five rabbits per group). Treatment of group 1. DS -0.04% in 1.4% polyvinylalcohol (PYA) was applied hourly from 0800h to 1900h daily (12 treatments) for 9 consecutive days (daily dose: 240 !J.g) except the initial day when treatment began immediately after virus inoculation and was administered 16 times (daily dose: 380 !J.g). Treatment of group 2. ACV (0.02% in 1.4% PYA) was applied at 2-h intervals from 0800h to 2000 h daily (five treatments) for 7 consecutive days, beginning 72 h after virus inoculation (daily dose: 50 !J.g). Group 3 received combined therapy with DS and ACV a Q = the quotient of the n-fold virus titre reduction of the drug combination and the product of the virus titre reductions by the individual drugs. If Q > 1, = 1 or <1 ; the interaction is synergistic, additive or antagonistic, respectively (Smith et et., 1982) . The values represent the mean of three independent determinations.
applied in the same manner as for each drug separately. Group 4, only infected eyes were treated with placebo (1.4% PVA). Rabbits whose eyes were scarified but not exposed to virus, were also treated with DS and/or ACV as toxicity controls and no toxicity was noted. Treatment was assigned on a random coded basis and all evaluations were done on a blind basis. Each eye was examined daily, after fluorescein staining, for corneal lesions. The severity of corneal lesions was scored as described by Maudgal et al. (1980) from grade 0 (uninfected) to grade 5 (totalcorneal ulcer). The significance of the results was assessed by Student's r-test (P values <0.05 were considered significant). Virus shredding was monitored by culture of the preocular tear film of all groups. The samples were taken daily, before the first treatment for the day, as described by Trousdale et al. (1990) and than virus titrations were done in microplates on HESMF cells. The severity of corneal lesions and the titre of virus shed in tear film cultures during OS, ACV and combination therapy, are presented in Fig. 1 . Topical application of OS and ACV alone resulted in clear reduction of corneal lesions, as compared to placebo-treated rabbits but on day 10 p.i, persistence of single punctate lesions in the eyes were observed. Following combination therapy with OS and ACV only separate punctate lesions were noted between days 4 and 8 which disappeared on day 9 after infection. Mean reductions in the keratitis scores, evaluated for the period from day 4 until day 10 were as follows:
OS, 38%; ACV, 68.6%; OS + ACV, 86.2%. For all groups the degree of corneal lesions were well correlated with the amount of virus in the tear film. By combination chemotherapy virus shedding no longer occurred on day 9, while in the control group, as well as in the OS and ACV treated groups, virus continued to be shed.
The effectivity of OS in the treatment of HSV-1 keratitis in rabbits and the emergence ofi~CV-resistant strains (Crumpacker et al., 1982; Smith et aI., 1980) justify the search for effective combinations of ACV with other virus inhibitors. The results of the present study can contribute to our knowledge of the therapy of herpesvirus infections.
